WeVote
Log In

Bill

Bill

SB 435

AN ACT AUTHORIZING THE STATE TO IMPORT THE ACTIVE INGREDIENTS OF CERTAIN DRUGS.

2025 Regular Session Introduced by Saud Anwar

Connecticut would authorize importing pharmaceutical active ingredients from other countries to reduce medication costs, though federal law and safety oversight create significant implementation barriers.

REF. TO JOINT COMM. ON General Law
#drugs #exportsandimports
0
WeVote Research Nonpartisan
Bill Summary · SB 435

Legislative bill overview

SB 435 would authorize Connecticut to import active pharmaceutical ingredients (APIs) from other countries, particularly Canada and potentially other nations with regulatory approval. This represents a state-level effort to circumvent federal restrictions on drug importation and could allow lower-cost medications to enter the Connecticut market through alternative supply chains.

Why is this important

Medication costs remain a significant burden for many Americans, and this bill directly addresses affordability at the state level. If successful, it could demonstrate a model for other states and potentially pressure federal policy changes, though it also carries implementation and safety complexities that would need resolution before any practical effect.

Potential points of contention

  • Federal legal authority: Federal law currently prohibits most drug importation; this bill may face constitutional challenges and conflict with FDA jurisdiction over drug safety and approval
  • Supply chain safety and quality control: Importing APIs requires robust verification systems to prevent contaminated, counterfeit, or substandard ingredients from entering the market
  • Pharmaceutical industry opposition: Drug manufacturers may argue this undermines patent protections, R&D investment incentives, and their existing distribution networks
  • Regulatory implementation unclear: The bill lacks detail on how Connecticut would verify safety, establish pricing, or coordinate with federal agencies without explicit legal authority
  • Manufacturer retaliation risks: Companies could restrict supply to Connecticut or raise prices for legitimate distributors in response

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.